The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study

Schizophrenia Research
Marvin S SwartzCATIE Investigators

Abstract

This double-blind study compared a second generation (atypical) antipsychotic drugs compared to a representative older agent for patients with schizophrenia who use or avoid illicit substances. Schizophrenic subjects were recruited at 57 U.S. sites and randomly assigned to olanzapine, perphenazine, quetiapine, risperidone or ziprasidone for up to 18 months. The primary aim of this analysis was to delineate differences between the overall effectiveness of these five treatments among patients who used or did not use illicit substances. There were no significant differences between treatment groups in time to all-cause treatment discontinuation among patients who use illicit drugs (median 3.3 to 6.8 months). Among non-users time to treatment discontinuation was significantly longer for patients treated with olanzapine (median 13.0 months) than perphenazine ( 5.9 months), risperidone (5.6 months), or quetiapine (5.0 months); time to discontinuation for ziprasidone (4.3 months) was even shorter, although the latter difference was not significant. The difference between risperidone and quetiapine, although small, was significant. All remaining differences were non-significant. Similar results were found for discontinuation due to ine...Continue Reading

References

Nov 21, 1990·JAMA : the Journal of the American Medical Association·D A RegierF K Goodwin
Jan 1, 1990·Schizophrenia Bulletin·R E DrakeM S Beaudett
Jan 1, 1989·The Journal of Nervous and Mental Disease·J P McEvoyL Roth
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
May 1, 1996·Schizophrenia Research·C D SwoffordL B Inderbitzin
Mar 18, 2000·Clinical Psychology Review·J J BlanchardA R Sherwood
Feb 24, 2001·American Journal of Public Health·S D RosenbergM P Salyers
Jan 5, 2002·Journal of Traumatic Stress·L A GoodmanUNKNOWN 5 Site Health and Risk Study Research Committee
Jan 5, 2002·Journal of Substance Abuse Treatment·K H LittrellC G Johnson
Oct 3, 2002·The British Journal of Psychiatry : the Journal of Mental Science·Robin G McCreadie, UNKNOWN Scottish Comorbidity Study Group
Nov 28, 2002·Journal of Clinical Psychopharmacology·John W TsuangDoug Tucker
Jun 19, 2004·The American Journal on Addictions·Santanu GoswamiGagandeep Singh
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Feb 2, 2006·The American Journal on Addictions·Ismene L PetrakisRobert Rosenheck
Apr 28, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Richard S E KeefeJeffrey A Lieberman
Dec 8, 2006·The American Journal of Psychiatry·Robert A RosenheckUNKNOWN CATIE Study Investigators
Jun 6, 2007·Archives of General Psychiatry·Richard S E KeefeUNKNOWN Neurocognitive Working Group

❮ Previous
Next ❯

Citations

Nov 18, 2008·Schizophrenia Bulletin·Peter F BuckleyDavid J Castle
Dec 5, 2015·Expert Opinion on Pharmacotherapy·Jean-Michel AzorinRaoul Belzeaux
Aug 3, 2010·Schizophrenia Research·Marc De HertRuud van Winkel
Nov 11, 2008·Schizophrenia Research·Robert A RosenheckJeffrey Lieberman
Feb 6, 2015·Psychological Medicine·F J van der MeerUNKNOWN Genetic Risk and Outcome of Psychosis (GROUP) Investigators
Aug 30, 2011·Schizophrenia Research·Karin E KerfootUNKNOWN CATIE Investigators
Feb 9, 2012·Schizophrenia Research·Daniel van DijkWim van den Brink
Aug 1, 2014·Frontiers in Psychiatry·Michel LejoyeuxMichaelle Ilongo
Jul 7, 2016·Progress in Neuro-psychopharmacology & Biological Psychiatry·Madeleine UysBrian H Harvey
May 26, 2012·Journal of Psychopharmacology·A R Lingford-HughesUNKNOWN British Association for Psychopharmacology, Expert Reviewers Group
Feb 5, 2011·Journal of Psychopharmacology·Thomas R E Barnes, UNKNOWN Schizophrenia Consensus Group of British Association for Psychopharmacology
Sep 10, 2017·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·David Crockford, Donald Addington
Jan 23, 2018·The Cochrane Database of Systematic Reviews·Henk S TemminghDan J Stein
Nov 20, 2013·The Cochrane Database of Systematic Reviews·Laila AsmalStefan Leucht
Feb 5, 2009·Expert Opinion on Pharmacotherapy·Thomas Wobrock, Michael Soyka
May 30, 2019·Nordic Journal of Psychiatry·Renata AlisauskieneErik Johnsen
Feb 18, 2012·The Cochrane Database of Systematic Reviews·Adib Essali, Ghassan Ali
Jan 5, 2014·The Cochrane Database of Systematic Reviews·Priya KhannaJun Xia
Mar 10, 2015·The Cochrane Database of Systematic Reviews·Benno HartungStefan Leucht
Oct 13, 2009·The Cochrane Database of Systematic Reviews·Katja KomossaStefan Leucht
Apr 8, 2010·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·George Foussias, Gary Remington
Apr 8, 2010·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Joseph P McEvoyHoward C Margolese
Jul 7, 2012·The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG·Scott A Price, Nancy C Brahm
Nov 28, 2020·Current Treatment Options in Oncology·Mellar P Davis, Gareth J Sanger
Jun 24, 2019·Psychiatry Research·Arsalan ArsalanMuhammad Ayub

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.